Implicit Bioscience

This was a planned phase 2 trial to test IC14, a monoclonal antibody, in 50 people with rapidly progressing ALS. Participants would have received intravenous IC14 or placebo twice weekly for 12 weeks. The study was withdrawn before any patients were enrolled, so no data on safety…

This study planned to test an experimental drug called IC14 in people with rapidly progressing ALS. The drug was given by IV over two weeks, and brain scans measured inflammation. However, the trial was withdrawn before enrolling any participants, so no data on safety or effectiv…

This study aimed to test a drug called IC14 in adults with early dengue fever to see if it is safe and could help reduce symptoms and viral levels. It was designed for people in areas where dengue is common, but the trial was withdrawn before any participants were enrolled. No re…

This study was designed to test whether IC14, a drug that blocks a key inflammatory signal, could help people with acute respiratory distress syndrome (ARDS). The plan was to give IC14 or a placebo to about 100 ICU patients and see if it reduced time on a ventilator. However, the…

This early-stage study tests a monoclonal antibody called atibuclimab (IC14) in 10 adults who had a severe heart attack (STEMI) and received a stent. The drug is given by IV to see if it can prevent further heart muscle damage and reduce inflammation. Participants are compared to…

This early-stage study tests whether the drug atibuclimab (IC14) is safe and helpful for adults hospitalized with sudden worsening heart failure. Ten participants receive one IV dose of the drug and are monitored for side effects, drug levels, and heart failure markers. The goal …